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Abstract
I In nt tr ro od du uc ct ti io on n: :   The aim of this study was to investigate the prognostic significance
of proliferating cell nuclear antigen (PCNA) expression in laryngeal carcinoma in
relation to clinicopathological features. Special emphasis was placed on examining
the relationship of PCNA expression in the primary tumour and PCNA expression
in corresponding lymph node metastases obtained from the same patients. 
M Ma at te er ri ia al l   a an nd d   m me et th ho od ds s: :   The study included 60 patients with advanced larynx
carcinoma who had received treatment and follow-up for at least 5 years. Sixty
laryngeal carcinoma specimens and metastatic lymph nodes from 24 patients
were examined for immunohistochemical PCNA expression.
R Re es su ul lt ts s: :   The percentages of PCNA positive cells were significantly higher in the
primary tumours which developed lymph node metastases than in those without
metastases. The fraction of PCNA immunolabelled cells in metastatic lymph
nodes increased significantly when compared with the PCNA positive cell score
in their corresponding primary tumours obtained from the same patient. There
was a significant difference in PCNA index score in primary tumours between
the group of patients who survived a 5-year period and those who died within
5 years after treatment.
C Co on nc cl lu us si io on ns s: :   Our data demonstrate that a high proliferation index in primary
larynx  tumours  is  retained  and  increased  in  corresponding  lymph  node
metastases. Measurement of the fraction of cancer cells stained for PCNA in
primary larynx carcinomas can be helpful in selecting tumours with high
aggressiveness potential that are more likely to develop neck metastases and
thereby in identifying patients who need elective lymph node dissection or
additional treatment.
K Ke ey y   w wo or rd ds s: :   proliferating cell nuclear antigen, larynx cancer, metastases.
Introduction
Predicting the outcome of laryngeal cancer is of utmost importance for
the physician to decide on the treatment modality. Detection of a lymph
node metastasis is the crucial factor in evaluating the necessity of neck
dissection and the extent of surgery in patients with advanced laryngeal
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carcinomas.  Clinical  examination  and  imaging
investigations of lymph node metastases such as
computed  tomography  (CT)  and  magnetic
resonance  imaging  (MRI)  are  helpful  in  the
diagnostic process, but they are associated with
false-positive or false-negative results [1-3]. Thus,
additional parameters of the tumour to predict its
more aggressive potential are needed, among them
immunohistological analysis. Although different
histological  tumour  biomarkers  are  not  direct
factors in predicting the occurrence of lymph node
metastases, their evaluation could help categorize
primary tumours with clinically more aggressive
potential. 
One of the most important criteria that show
aggressive  biological  behaviour  is  the  cellular
proliferation rate of the tumour. Cell proliferation in
a retrospective study involving archival material is
mainly  measured  by  means  of  immunohisto-
chemical  expression  of  Ki-67  protein  and
proliferating cell nuclear antigen (PCNA) [4, 5].
Proliferating  cell  nuclear  antigen  is  a DNA
polymerase-associated protein needed for DNA
replication and repair [6]. Proliferating cell nuclear
antigen appears in late G1 phase, increases during
S phase, and declines during G2 and M phases of
the cell cycle [7], and is a potential biomarker of
a variety of tumours [8-10], including laryngeal
carcinomas [11-17]. The fraction of PCNA positive
cells progressively increases with the degree of
epithelial hyperplasia in the larynx [18, 19], and
inversely  correlates  with  the  degree  of  dif-
ferentiation in larynx cancer [14, 15, 20]. The ratio
of PCNA positive cells was also related to the
occurrence of nodal metastases [11-14, 17] and
PCNA immunolabelling in biopsy specimens was
useful in identifying patients with clinically negative
lymph nodes who were at considerable risk of
occult metastases and may benefit from elective
neck dissection [15]. However, these results are in
contradiction  to  other  reports  showing  no
association between PCNA expression and presence
of  neck  metastases  [20-22].  Although  several
studies have implicated factors measuring cell
proliferation in laryngeal tumours, only one has
examined their expression in metastatic deposits
[15].  Because  therapy  is  also  targeted  toward
metastatic disease, the assumption is made that
expression of the tumour marker in secondary
lesions  reflects  the  situation  observed  in  the
primary tumour. To investigate this suggestion, the
present study has evaluated the expression of the
PCNA antigen in primary laryngeal carcinomas and
their corresponding lymph node metastases in
order to identify tumours which are more likely to
metastasize. 
Material and methods
P Pa at ti ie en nt ts s
The  study  included  60  patients,  who  were
diagnosed with laryngeal cancer and underwent
surgical treatment. Of these patients, 15 required
total laryngectomies (TL), 11 total laryngectomies
followed by radiotherapy (TL/RD), 12 total laryn-
gectomies and functional neck dissection (TL/ND),
and  22  total  laryngectomies  and  radical  neck
dissection followed by radiotherapy (TL/ND/RD).
Patient data are summarized in Table I.
S Sl li id de e   p pr re ep pa ar ra at ti io on n   a an nd d   s se ec ct ti io on n   a an na al ly ys si is s
Paraffin-embedded 4.5 ﾵM thin sections were
stained with haematoxylin and eosin and assessed
histopathologically. Immunohistochemical analysis
of proliferating cell nuclear antigen was performed
on 60 laryngectomy specimens and on 24 lymph
node metastasis specimens using the avidin-biotin-
peroxidase technique. In brief, specimens were
dewaxed with xylene, dehydrated in ethanol and
incubated in 3% hydrogen peroxide for 5 min to
exhaust endogenous peroxidase activity. Epitope
unmasking was performed using 0.1% trypsin, 0.1%
CaCl2 and 0.05 M Tris solution (pH 7.6) for 20 min
at room temperature. After blocking in normal
bovine serum, tissue sections were incubated with
1 : 100 diluted monoclonal PC10 antibody (Dako,
Glostrup, Denmark). Biotynylated rabbit anti-mouse
C Ch ha ar ra ac ct te er ri is st ti ic c N Nu um mb be er r   o of f   p pa at ti ie en nt ts s
Total number
Median age (range)
Male/female
Tumour grading:
• well differentiated (G1)
• moderately differentiated (G2)
• poorly differentiated (G3)
TNM classification:
• T2
• T3
• T4
• N0
• N1
• N2
• N3
Clinical stage:
• II
• III
• IV
T Ta ab bl le e   I I. . Patient characteristics
60
55 (34-77)
57/3
10
37
13
8
34
18
32
6
15
7
7
23
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immunoglobulin (Dako, Glostrup, Denmark) was
diluted 1 : 300 and used as a secondary antibody.
Proliferating cell nuclear antigen expression was
assessed in tumour areas showing the highest
density of staining, as determined by an initial scan
at a magnification of 40ￗ. For PCNA index counting,
at 200ￗ the field in each of the most stained areas
was counted and the average count determined.
The  growth  fraction  by  PCNA  staining  was
evaluated by counting 500 consecutive cells for
each tumour and an index of positive cells to total
number  of  cells  was  scored.  All  pathological
material was reviewed by two pathologists without
knowledge  of  the  clinical  outcome  and  other
clinicopathological features. Because of the PCNA
scoring discrepancy between pathologists, samples
of lymph node metastases from 4 patients were
removed from the study.
S St ta at ti is st ti ic ca al l   a an na al ly ys si is s
Proliferating cell nuclear antigen immunostaining
values  (mean  ﾱ  SD)  were  compared  with
clinicopathological factors by means of ANOVA test,
paired Student’s t-test, and Pearson’s correlation
test. A value of p < 0.05 was considered to be
statistically significant. 
Results
P Pr ro ol li if fe er ra at ti in ng g    c ce el ll l    n nu uc cl le ea ar r    a an nt ti ig ge en n    i in nd de ex x   
i in n   p pr ri im ma ar ry y   t tu um mo ou ur rs s   a an nd d   l ly ym mp ph h   n no od de e   m me et ta as st ta as se es s
Positive PCNA immunostaining was found in all
60 larynx tumours and all analyzed lymph node
metastases from 24 patients. The PCNA index in
laryngeal carcinoma ranged from 15.8 to 73.0% and
from 50.4 to 87.4% in lymph node metastases. The
percentages of PCNA positive cells were significantly
higher in the primary tumours associated with
lymph node metastases than in those without
metastases (Table II). We also analyzed the degree
of cell proliferation directly in metastatic lymph
nodes of 24 patients. The fraction of PCNA stained
cells  in  metastatic  lymph  nodes  increased
significantly when compared with the PCNA positive
cell score in their corresponding primary tumours
as calculated by means of paired Student’s t-test
(p  <  0.001)  and  Pearson’s  correlation  test 
(p = 0.011). Mean index of PCNA positive cells was
69.97 ﾱ10.09% (n = 24) in metastases vs. 50.27
ﾱ12.89%  (n =  28)  in  primary  tumours  which
developed metastases. 
P PC CN NA A   s sc co or re e   a an nd d   T TN NM M/ /c cl li in ni ic ca al l   c cl la as ss si if fi ic ca at ti io on n
Clinical stage of neoplastic disease is often
characterized by TNM classification. In our study
the mean PCNA proliferation index was the highest
in advanced larynx cancers classified as clinical
TNM stage IV, and decreased in tumours obtained
from patients with clinical TNM stages III and II of
the disease. ANOVA test analysis revealed that
differences  between  these  three  values  were
statistically significant. There was no significant
association between mean proliferation rate and
T stage. 
P Pr ro ol li if fe er ra at ti in ng g    c ce el ll l    n nu uc cl le ea ar r    a an nt ti ig ge en n    i in nd de ex x   
a an nd d   h hi is st to ol lo og gi ic ca al l   g gr ra ad de e   o of f   t th he e   t tu um mo ou ur r
There was also a significant inverse correlation
between PCNA mean proliferation index in primary
larynx carcinoma and histological grade measured
by means of ANOVA test. Mean score of PCNA
positive cells was highest in poorly differentiated
(G3)  carcinomas,  decreased  in  moderately
differentiated (G2) carcinomas, and was the lowest
in well differentiated (G1) carcinomas (Table II). 
P Pr ro ol li if fe er ra at ti in ng g    c ce el ll l    n nu uc cl le ea ar r    a an nt ti ig ge en n    s sc co or re e   
a an nd d   o ov ve er ra al ll l   s su ur rv vi iv va al l   r ra at te e
We observed that mean PCNA index in primary
tumours  was  lower  in  patients  who  survived 
a 5-year period (Table II). However, having analyzed
the  PCNA  score  in  connection  with  different
treatment modalities, such a correlation was found
only in the group of patients that underwent total
F Fa ac ct to or r P PC CN NA A   i in nd de ex x    N Nu um mb be er r p p V Va al lu ue e
( (% %   p po os si it ti iv ve e   c ce el ll ls s) ) o of f   p pa at ti ie en nt ts s
i in n   p pr ri im ma ar ry y   t tu um mo ou ur rs s
Tumour grading:
• G1 31.63 ﾱ11.06 10 0.006
• G2 45.01 ﾱ15.64 37
• G3 51.43 ﾱ12.03 13
T stage:
• T2 36.88 ﾱ23.66 8 0.33
• T3 44.70 ﾱ12.99 34 (NS)
• T4 46.44 ﾱ15.18 18
Presence of lymph node metastases:
• N0 38.84 ﾱ15.54 32 0.003
• N1-3 50.27 ﾱ12.89 28
Clinical stage:
• II 31.84 ﾱ20.39 7 0.036
• III 42.95 ﾱ13.64 23
• IV 47.98 ﾱ15.37 30
5-year survival:
• alive 39.23 ﾱ16.06 26 0.025
• died 48.11 ﾱ13.77 34
T Ta ab bl le e   I II I. .   Correlation between PCNA index and patho-
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laryngectomy followed by radiotherapy (p < 0.05).
A similar relationship was observed in patients who
received other treatments but it was not statistically
significant (Table III, Figure 1). 
Discussion
Detection or prediction of the occurrence of
lymph node metastases in patients with larynx
cancer  is  a crucial  step  in  the  assessment  of
advancement of the disease state, which influences
further therapeutic strategy and clinical outcome. 
In general, high proliferative activity in larynx
cancer is associated with a worse clinical outcome,
including recurrence, shorter survival time and
presence of metastases. However, the majority of
performed studies analyzed the Ki-67 or PCNA
proliferation indices only in primary cancers and
then correlated these values with the occurrence
of neck metastases [11-13, 16, 17, 20-22]. Very rare
are reports where the authors assessed the degree
of  cell  proliferation  directly  in  lymph  node
metastases. In one of such studies the number of
analyzed cases was limited to 10 lymph nodes
derived  from  patients  with  laryngeal  and
hypopharyngeal cancers [15]. In our study, we
performed an analysis of PCNA expression in lymph
node metastases obtained from 24 patients who
developed exclusively laryngeal carcinoma. We have
noted a very high percentage of PCNA positive cells
in all single metastasis specimens – the lowest
score was over 50% of total cells and mean PCNA
index was near 70% in metastatic lymph node
samples. Paired t-test and Pearson’s correlation test
showed a positive correlation between increased
PCNA index in metastases and lower PCNA index
in corresponding primary carcinoma obtained from
the same patient. Liu et al. [15] reported similar
results,  demonstrating  higher  PCNA  index  in
metastases  than  in  primary  carcinomas.  Ad-
ditionally, we have shown that laryngeal tumours
associated  with  neck  metastases  were
characterized  by  increased  PCNA  index  when
compared  with  tumours  without  lymph  node
metastases,  which  is  consistent  with  a great
number of studies [11-17] and in contradiction to
only a few reports [20-22]. It is plausible that
metastasizing laryngeal carcinomas could develop
a cell population with highly proliferative potential,
and this potential is retained in arising metastases.
Although  PCNA  is  not  directly  involved  in  the
metastatic behaviour of cancer cells, it could be
a good prognosticator for the selection of tumours
which are prone to metastasis. 
Increased cell proliferation is regarded as one of
the  most  important  biological  mechanisms  in
oncogenesis.  Proliferating  cell  nuclear  antigen
expression is often associated with other proteins
involved  in  cell  cycle  progression.  A positive
correlation between PCNA expression and over-
expression of cyclin-dependent kinase 2 (CDK2) [23],
cyclin A [24], cyclin E [25], cyclin-dependent kina-
se 4 (CDK4) and cyclin D1 [26] has been found in
laryngeal  carcinoma,  which  indicates  a close
association  between  PCNA  expression  and
proliferation activity of tumour cells. The property
of cell proliferation is related to the progression of
various malignancies and influences disease-free
and overall survival [4, 10, 14]. In our study we
demonstrated that mean PCNA index is negatively
correlated with 5-year survival rate in the group of
patients  who  underwent  total  laryngectomy
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F Fi ig gu ur re e   1 1. .   Correlation between PCNA index in primary
larynx  tumour,  treatment  modality  and  5-year
survival period
TL – total laryngectomy, RD – radiotherapy, ND – neck
dissection, *p < 0.05, Student’s t-test
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5 5   y ye ea ar rs s w wi it th hi in n   5 5   y ye ea ar rs s s si ig gn ni if fi ic ca an nc ce e
TL (n = 15) 383.7 ﾱ38.73  (n = 11) 521.3 ﾱ60.61  (n = 4) p = 0.0813, ns
TL + RD (n = 11) 318.6 ﾱ55.58  (n = 5) 571.2 ﾱ65.59  (n = 6) p = 0.0186*
TL + ND (n = 12) 432.2 ﾱ63.43  (n = 5) 483.9 ﾱ57.21  (n = 7) p = 0.5565, ns
TL + ND + RD (n = 22) 481.8 ﾱ129.1  (n = 5) 504.3 ﾱ29.17  (n = 17) p = 0.7930, ns
TL – total laryngectomy, RD – radiotherapy, ND – neck dissection, (Student’s t-test, *p < 0.05, ns – not significant)
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followed by radiotherapy. This tendency was also
shown in the group of patients that received other
treatment modalities, although the differences were
not significant and decreased according to more
aggressive therapy applied (LT/RD vs. LT/ND vs.
LT/ND/RD),  which  was  also  connected  with
increasing  clinical  stage  of  the  disease.  Since
patients were qualified for different treatment
modalities  according  to  clinical  examinations,
histological type and grading of the primary tumour,
and imaging investigations (CT, occasionally also
lymphoscintigraphy), the type of treatment was
dependent  on  clinical  stage  of  the  neoplastic
disease. Therefore differences between PCNA scores
measured in the group of patients who survived
and those who died within a 5-year period and
received the same therapy could to some extent
reflect the proliferation potency of larynx tumours;
however, they are greatly influenced by the local
progression of the neoplastic disease. The PCNA
index assessment was more prognostic in the
group of patients with less advanced disease who
also received less aggressive therapy. The high
PCNA score found in this group of patients should
draw our attention to considering more aggressive
therapy 
Several  studies  have  reported  increased
proliferative indices associated with tumour grade
[14, 16, 20, 21]. The grade of laryngeal carcinoma
was an important factor affecting recurrence [27],
and  thereby  together  with  biological  markers
reflecting tumour proliferation potential could be
useful for the detection of tumours that require
more aggressive treatment [28]. We observed an
inverse  correlation  between  PCNA  index  and
tumour grading. These findings are consistent with
some studies [14, 16, 20, 21] and in contradiction to
others  [12,  22].  More  detailed  histological
examinations showed that PCNA immunostaining
corresponds to the histological grade of benign
epithelial hyperplastic lesions and squamous cell
carcinoma  of  the  larynx  [18,  19].  In  well  dif-
ferentiated, keratinizing carcinomas, PCNA staining
was  observed  in  layers  adjacent  to  the  basal
membrane at the periphery of the tumour islands,
while  in  less  differentiated,  non-keratinizing
carcinomas, the number of PCNA positive cells
increased  and  they  tended  to  be  dispersed
throughout the sample [19]. It was also reported
that immunostaining of PCNA was heterogeneous
within each laryngeal carcinoma and varied widely
between tumours [14], which could be responsible
for the observed discrepancy between different
reports.  
Despite these practical limitations, the pre-
therapeutic assessment of PCNA expression may
become of increasing importance in the evaluation
of tumour aggressiveness and of prognostic value
in predicting neck metastases in patients with
laryngeal carcinoma, especially when analyzed in
preoperative biopsy specimens [15]. 
In conclusion, our data demonstrate that a high
proliferation index in primary larynx tumours is
retained and increased in corresponding lymph
node metastases. The measurement of the fraction
of cancer cells stained for PCNA in the primary
larynx  carcinomas  can  be  helpful  in  selecting
tumours with high aggressiveness potential that
are more likely to develop neck metastases, and
thereby in identifying patients who need elective
lymph node dissection or additional treatment. 
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